Kiadis Pharma Updates On ATIR

Kiadis Pharma said that ATIR continues to show positive clinical results in patients who received a mismatched bone marrow transplantation from a family member donor.

ATIR is a cell based product of mismatched donor immune cells from which the acute Graft versus Host Disease (GvHD) causing cells have been removed. By eliminating the risk of severe acute GvHD, the prophylactic use of immune suppressants can be avoided post transplantation, quickly giving patients a functioning immune system and ultimately resulting in a reduced Transplant Related Mortality (TRM).

Kiadis Pharma claimed that the two year follow up data from the Phase I/II study show no Transplant Related Mortality (TRM) in a group of 10 high risk leukemia patients who received an efficacious dose of ATIR. The overall survival of this group after two years is 70%. These results compare to outcomes of bone marrow transplantations from a full matching donor.

Additionally, the FDA has granted ATIR an orphan arug designation as a cell based therapy for the reduction of Transplant Related Mortality caused by Graft versus Host Disease GvHD and/or infections following allogeneic bone marrow transplantation.

Manja Bouman, CEO of Kiadis Pharma, said: “The FDA’s decision to grant ATIR an Orphan Drug Designation underscores the potential of our program for bone marrow transplant patients and their families. We are excited and encouraged by the clinical success to date, and are focused on rapidly developing ATIR to better serve this patient community.”